Development of therapeutic drugs targeting SARS-CoV-2 infection or replication is an urgent need for the treatment of COVID-19.57, 58, 59, 60, 61 The potential therapeutic targets of COVID-19 include the following: (1) the NSPs: pp1a and pp1ab are cut by proteases (PLpro) and 3CLpro or Mpro to produce multiple NSPs, including RdRp, helicase, and nsp16. This evidence concerns the gene PPP1CA and COVID-19.